Changes in rosacea comorbidities and treatment utilization over time

Journal of Drugs in Dermatology

Volumn 9, Issue 11, 2010, Pages 1402-1406

  Yentzer, Brad A ^a   Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; DOXYCYCLINE; KETOCONAZOLE; METRONIDAZOLE; MINOCYCLINE; PIMECROLIMUS; SULFACETAMIDE; SULFACETAMIDE PLUS SULFUR; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT;

ARTICLE; COMORBIDITY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; ROSACEA; TREND STUDY; CLINICAL PRACTICE; DRUG UTILIZATION; SKIN DISEASE; STATISTICS;

ANTI-BACTERIAL AGENTS; DERMATOLOGIC AGENTS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; ROSACEA; SKIN DISEASES;

EID: 79952108843     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dahl MV. Rosacea subtypes: A treatment algorithm. Cutis. 2004;74:21-24.
2. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912. (Pubitemid 38685771)
3. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341. (Pubitemid 39178655)
4. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol. 1999;79:456-459.
5. McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1:191-199.
6. Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: The safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat. 1997;8:79-85. (Pubitemid 27338511)
7. Nally JB, Berson DS. Topical therapies for rosacea. J Drugs Dermatol. 2006;5:23-26.
8. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802. (Pubitemid 46561002)
9. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: Focus on antibiotic resistance. Cutis. 2007;79(6 Suppl):9-25
10. Balkrishnan R, McMichael AJ, Hu JY, et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol. 2006;45:111-115.
11. National Rosacea Society. What is rosacea? Available at www.rosacea. org. Accessed 05 June 2009.
12. Nicholson K, Abramova L, Chren MM, et al. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol. 2007;57:213-221. (Pubitemid 47053981)
13. Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol. 2008;7:41-49.
14. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: Implications for the dermatologist. Dermatol Clin. 2007;25:127-132. (Pubitemid 46566394)
15. Bikowski JB, Goldman MP. Rosacea: Where are we now? J Drugs Dermatol. 2004;3:251-261.
16. th Annual Meeting of the American Academy of Dermatology; March 6-10; San Francisco, CA. 2009.
17. Bojar R, Holland K. Azelaic acid: A review of its antimicrobial properties. Rev Contemp Pharmacother. 1993;4:403-414.
18. Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43:381-387. (Pubitemid 38714606)
19. Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis. 2004;73:11-17. (Pubitemid 38843992)
20. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845. (Pubitemid 36706214)
21. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77:3-11. (Pubitemid 43723532)
22. Elewski BE, Fleischer AB Jr., Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: Results of a randomized trial. Arch Dermatol. 2003;139:1444-1450. (Pubitemid 37433134)
23. Thiboutot DM, Fleischer AB Jr., Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7:541-546.
24. DrugStore.Com. Available at http://www.drugstore.com. Accessed 15 June 2009.
25. Colon LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis. 2007;79:317-321.
26. Draelos ZD, Green BA, Edison BL. An evaluation of polyhydroxy acid skin care regimen in combination with azeleic acid 15% gel in rosacea patients. J Cosmet Dermatol. 2006;5:23-29.
27. Wise RD. Submicrobial doxycycline and rosacea. Compr Ther. 2007;33:78-81. (Pubitemid 350242504)